NCT02977208View on ClinicalTrials.gov

Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use

PHASE4CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
EpilepsyChronic Pain
Interventions
PROCEDURE

Sparse blood sampling

Blood samples are being collected at times 0, 90 and 240 minutes after gabapentin administration.

PROCEDURE

Urine sampling

Urine samples are being collected during the dosing interval, only in patients hospitalized at Hospital Estadual de Américo Brasiliense (HEAB).

PROCEDURE

DNA extraction

Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G\>T and SLC22A4 c.1507C\>T polymorphisms

DRUG

Gabapentin

All patients undergoing chronic treatment with gabapentin are being recruited.

Trial Locations (1)

14800903

Universidade Estadual Paulista Júlio de Mesquita Filho, Araraquara

All Listed Sponsors
collaborator

University of Sao Paulo

OTHER

lead

São Paulo State University

OTHER

NCT02977208 - Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use | Biotech Hunter | Biotech Hunter